Skip to main content

Table 4 Impact of clinical variables on urinary, bowel and sexual quality-of-life as well as acute genitourinary toxicity

From: Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer

Domain

Covariate

Declined QOL/Toxicity Occurrence a

P

OR d

95%CI d

Adjusted P

Yes

No

Irritation/obstruction

Age

69.5 (65, 75.5)

71 (66, 76.5)

0.535

0.954

0.874–1.053

1.043

 

Baseline score

92.9 (85.7, 98.2)

89.3 (80.3, 96.4)

0.275

–

–

–

 

TURP

33.3%

9.6%

0.036

5.699

1.157–28.08

0.032

 

Prescribed dose (59.2–60.8 GyE/16 Fx)

75.0%

71.2%

0.999

–

–

–

 

Acute GU toxicity

25.0%

38.5%

0.73

–

–

–

 

IPSS ≥8

50.0%

50.0%

0.884

–

–

–

 

Castration b

66.7%

48.1%

0.742

–

–

–

Incontinence

Age

69 (67, 76)

71 (66, 76)

0.669

1.000

0.908–1.101

0.997

 

Baseline score

100 (91.8, 100)

100 (100, 100)

0.552

–

–

–

 

TURP

45.5%

7.5%

0.002

10.214

2.064–50.54

0.004

 

Prescribed dose (59.2–60.8 GyE/16 Fx)

63.6%

73.6%

0.475

–

–

–

 

Acute GU toxicity

45.5%

34.0%

0.339

–

–

–

 

IPSS ≥8

72.7%

45.3%

0.179

–

–

–

 

Castration b

45.5%

52.8%

0.296

–

–

–

Bowel

Age

69.5 (65,75.5)

71.5 (67,77)

0.166

0.914

0.840–0.994

0.035

 

Baseline score

96.4 (90.2, 100)

89.3 (81.2, 98.2)

0.018

1.102

1.025–1.184

0.008

 

Prescribed dose (59.2–60.8 GyE/16 Fx)

71.9%

71.9%

1.000

–

–

–

 

Aspirin therapy

15.6%

6.3%

0.426

–

–

–

 

Hemorrhoids

25.0%

12.5%

0.337

–

–

–

 

Castration b

62.5%

40.6%

0.08

2.799

0.889–8.813

0.079

Sexual

Age

69 (66, 74)

71 (66, 76)

0.726

0.924

0.816–1.046

0.212

 

Baseline score

32.7 (26.9, 49.4)

20.1 (2.2, 29.8)

0.007

1.087

1.032–1.144

0.001

 

TURP

23.5%

11.8%

0.152

–

–

–

 

Prescribed dose (59.2–60.8 GyE/16 Fx)

76.5%

58.8%

0.337

–

–

–

 

Castration b

64.7%

41.2%

0.054

13.73

1.987–94.96

0.008

Acute GU toxicity

Age

69 (64, 75)

71 (66, 77)

0.255

0.950

0.875–1.032

0.226

 

TURP

14.3%

14.0%

0.972

–

–

–

 

Prescribed dose (59.2–60.8 GyE/16 Fx)

57.1%

79.1%

0.069

3.172

0.894–11.26

0.074

 

IPSS ≥8

76.2%

37.2%

0.004

5.485

1.601–18.79

0.007

 

Castration c

95.2%

95.3%

0.984

–

–

–

  1. a In the column are the percentage of patients or median values (IQR) having the corresponding outcomes of declined quality-of-life or acute toxicity
  2. b Maintaining castration till last follow-up
  3. c Castrated refers to the patients receiving hormone therapy during carbon ion irradiation therapy
  4. d These values were after multivariable adjustment
  5. QOL quality of life, TURP transurethral resection of the prostate, GU genitourinary, IPSS international prostate symptom score
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us